The challenge of scleroderma ulcers

Michele Ramien, Alain Brassard

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ulcers are common in systemic sclerosis, but the etiologies are diverse and often multifactorial. It is important to discern the primary factors contributing to ulcer formation in individual patients to devise therapeutic regimens effectively. Clinical symptoms such as the absence or presence of RP are useful to identify vasospasm as a causative factor. A biopsy may be helpful to distinguish vasculitic from thromboembolic ulcers if the clinical picture is not clear. Once the main etiologies are identified, appropriate therapies can be selected. Patients with systemic sclerosis who have never had an ulcer should be educated to avoid RP triggers and stop smoking. RP should be treated. Statins with or without acetylsalicylic acid should be started. Systemic sclerosis patients with healed ulcers should receive the same therapy as above with the addition of maintenance therapy with a dual vasodilatory-endothelial protective agent such as a PDE5I or bosentan that are both well tolerated and safe to continue on an indefinite basis with appropriate monitoring. Patients with active ulcers should be treated with standard care, including pain control, wound care with hydrocolloid occlusion dressings, and antibiotics as needed for superinfection. Treatment to reduce ischemia and improve healing should be tailored to the patient's ulcer etiology. Despite interesting recent developments in treatment, systemic sclerosis ulcers will continue to be a therapeutic challenge until the pathogenesis of the disease itself is better elucidated and directed, and individualized therapies can be developed. A systematic approach that attacks the ulcerpromoting process at its roots - most importantly targeting vasoconstriction, endothelial dysfunction, and vessel damage and integrity - is necessary to treat these challenging ulcers properly.

Original languageEnglish (US)
JournalJournal of Cutaneous Medicine and Surgery
Volume13
Issue numberSUPPL. 1
DOIs
StatePublished - Nov 18 2009
Externally publishedYes

Fingerprint

Ulcer
Systemic Scleroderma
Therapeutics
Hydrocolloid Bandages
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Protective Agents
Superinfection
Vasoconstriction
Aspirin
Ischemia
Smoking
Anti-Bacterial Agents
Biopsy
Pain
Wounds and Injuries

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

The challenge of scleroderma ulcers. / Ramien, Michele; Brassard, Alain.

In: Journal of Cutaneous Medicine and Surgery, Vol. 13, No. SUPPL. 1, 18.11.2009.

Research output: Contribution to journalArticle

@article{f19b249562964dd09688bf9c6560b753,
title = "The challenge of scleroderma ulcers",
abstract = "Ulcers are common in systemic sclerosis, but the etiologies are diverse and often multifactorial. It is important to discern the primary factors contributing to ulcer formation in individual patients to devise therapeutic regimens effectively. Clinical symptoms such as the absence or presence of RP are useful to identify vasospasm as a causative factor. A biopsy may be helpful to distinguish vasculitic from thromboembolic ulcers if the clinical picture is not clear. Once the main etiologies are identified, appropriate therapies can be selected. Patients with systemic sclerosis who have never had an ulcer should be educated to avoid RP triggers and stop smoking. RP should be treated. Statins with or without acetylsalicylic acid should be started. Systemic sclerosis patients with healed ulcers should receive the same therapy as above with the addition of maintenance therapy with a dual vasodilatory-endothelial protective agent such as a PDE5I or bosentan that are both well tolerated and safe to continue on an indefinite basis with appropriate monitoring. Patients with active ulcers should be treated with standard care, including pain control, wound care with hydrocolloid occlusion dressings, and antibiotics as needed for superinfection. Treatment to reduce ischemia and improve healing should be tailored to the patient's ulcer etiology. Despite interesting recent developments in treatment, systemic sclerosis ulcers will continue to be a therapeutic challenge until the pathogenesis of the disease itself is better elucidated and directed, and individualized therapies can be developed. A systematic approach that attacks the ulcerpromoting process at its roots - most importantly targeting vasoconstriction, endothelial dysfunction, and vessel damage and integrity - is necessary to treat these challenging ulcers properly.",
author = "Michele Ramien and Alain Brassard",
year = "2009",
month = "11",
day = "18",
doi = "10.2310/7750.2009.00010",
language = "English (US)",
volume = "13",
journal = "Journal of Cutaneous Medicine and Surgery",
issn = "1203-4754",
publisher = "Decker Publishing",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The challenge of scleroderma ulcers

AU - Ramien, Michele

AU - Brassard, Alain

PY - 2009/11/18

Y1 - 2009/11/18

N2 - Ulcers are common in systemic sclerosis, but the etiologies are diverse and often multifactorial. It is important to discern the primary factors contributing to ulcer formation in individual patients to devise therapeutic regimens effectively. Clinical symptoms such as the absence or presence of RP are useful to identify vasospasm as a causative factor. A biopsy may be helpful to distinguish vasculitic from thromboembolic ulcers if the clinical picture is not clear. Once the main etiologies are identified, appropriate therapies can be selected. Patients with systemic sclerosis who have never had an ulcer should be educated to avoid RP triggers and stop smoking. RP should be treated. Statins with or without acetylsalicylic acid should be started. Systemic sclerosis patients with healed ulcers should receive the same therapy as above with the addition of maintenance therapy with a dual vasodilatory-endothelial protective agent such as a PDE5I or bosentan that are both well tolerated and safe to continue on an indefinite basis with appropriate monitoring. Patients with active ulcers should be treated with standard care, including pain control, wound care with hydrocolloid occlusion dressings, and antibiotics as needed for superinfection. Treatment to reduce ischemia and improve healing should be tailored to the patient's ulcer etiology. Despite interesting recent developments in treatment, systemic sclerosis ulcers will continue to be a therapeutic challenge until the pathogenesis of the disease itself is better elucidated and directed, and individualized therapies can be developed. A systematic approach that attacks the ulcerpromoting process at its roots - most importantly targeting vasoconstriction, endothelial dysfunction, and vessel damage and integrity - is necessary to treat these challenging ulcers properly.

AB - Ulcers are common in systemic sclerosis, but the etiologies are diverse and often multifactorial. It is important to discern the primary factors contributing to ulcer formation in individual patients to devise therapeutic regimens effectively. Clinical symptoms such as the absence or presence of RP are useful to identify vasospasm as a causative factor. A biopsy may be helpful to distinguish vasculitic from thromboembolic ulcers if the clinical picture is not clear. Once the main etiologies are identified, appropriate therapies can be selected. Patients with systemic sclerosis who have never had an ulcer should be educated to avoid RP triggers and stop smoking. RP should be treated. Statins with or without acetylsalicylic acid should be started. Systemic sclerosis patients with healed ulcers should receive the same therapy as above with the addition of maintenance therapy with a dual vasodilatory-endothelial protective agent such as a PDE5I or bosentan that are both well tolerated and safe to continue on an indefinite basis with appropriate monitoring. Patients with active ulcers should be treated with standard care, including pain control, wound care with hydrocolloid occlusion dressings, and antibiotics as needed for superinfection. Treatment to reduce ischemia and improve healing should be tailored to the patient's ulcer etiology. Despite interesting recent developments in treatment, systemic sclerosis ulcers will continue to be a therapeutic challenge until the pathogenesis of the disease itself is better elucidated and directed, and individualized therapies can be developed. A systematic approach that attacks the ulcerpromoting process at its roots - most importantly targeting vasoconstriction, endothelial dysfunction, and vessel damage and integrity - is necessary to treat these challenging ulcers properly.

UR - http://www.scopus.com/inward/record.url?scp=68349116335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349116335&partnerID=8YFLogxK

U2 - 10.2310/7750.2009.00010

DO - 10.2310/7750.2009.00010

M3 - Article

VL - 13

JO - Journal of Cutaneous Medicine and Surgery

JF - Journal of Cutaneous Medicine and Surgery

SN - 1203-4754

IS - SUPPL. 1

ER -